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Stroke—Eprosartan Compared to Nitrendipine for Secondary
Prevention’). Costs and utilities were derived from published
estimates considering country-speciﬁc health care payer perspec-
tives. Drug prices of the comparators were based on the cheapest
generics. The treatment time horizon simulated was 2.5 years
(mean observation period of the MOSES study) modelling
follow-up effects over a life-time. Costs and effects were dis-
counted according to country-speciﬁc guidelines. RESULTS:
During a 2.5-year treatment time horizon modelling follow-up
effects over lifetime in 1,000 patients eprosartan treatment
avoided about 58 events (26 cardiovascular, 32 cerebrovascular)
and produced about 30 incremental QALYs versus the compared
treatments. Irrespective of country and comparator the cost per
QALY gained by eprosartan never exceeded €20,000 and there-
fore went far below the estimated willingness-to-pay threshold of
€30,000. The probabilistic sensitivity analyses fortify these out-
comes by showing a probability of 90–100% that eprosartan is a
cost-effective treatment strategy. CONCLUSION: Even compar-
ing eprosartan to low-priced generic substances, the HEALTH
model simulations provide evidence that eprosartan treatment is
associated with obvious health beneﬁts being obtained at reason-
able cost. Eprosartan should therefore be considered a good
treatment option for hypertensive patients with cerebrovascular
disease.
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OBJECTIVES: To examine in randomized controlled trial the
effectiveness and cost-effectiveness of arthroscopic acromioplasty
in the treatment of stage II shoulder impingement syndrome.
METHODS: We divided 140 patients into supervised exercise
program (n = 70, exercise group) and arthroscopic acromio-
plasty, followed by a similar exercise program (n = 70, combined
treatment group). The primary health outcome measure was
self-reported pain on a 0–10 Visual Analogue Scale at 24 months
with a two-point change deﬁned as minimal clinically important
difference (MCID). RESULTS: Results In an intention-to-treat
analysis an improvement exceeding MCID took place from base-
line to 24 months in both groups: self-reported pain diminished
from 6.5 to 2.9 in the exercise group (N = 66) and from 6.4 to
2.5 in the combined treatment group (n = 68) (P < 0.001 in
both). In the combined treatment group pain relief was attained
faster, but the groups did not any more differ at 24 months
(P = 0.37). A similar pattern was seen in the secondary outcome
measures: disability, pain at night, SDQ score, ability to work,
number of painful days and proportion of pain-free patients. The
mean total cost was €2961 in the combined treatment group and
€1864 in the exercise group. The incremental cost-effectiveness
ratio was €5852 per MCID unit, i.e., combined treatment was
considerably more costly. CONCLUSION: Arthroscopic acro-
mioplasty does not provide any signiﬁcant additional value over
structured and supervised exercise program alone in terms of
subjective outcome or cost-effectiveness. Operative treatment
should be offered judiciously.
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OBJECTIVES: For patients with renal failure who from amedical
perspective can be treated with either haemodialysis (HD) or
peritoneal dialysis (PD), the choice of treatment ismainly based on
administrative, economic and patient preference considerations.
HD is performed 3–5 times per week in a hospital, while PD is
performed daily at home. Both are ﬁnanced over hospitals’
budgets inNorway. This evaluation compared the costs ofHDand
PD from both a societal and a hospital perspective for such
patients. METHODS: Costs were calculated based on national
data on resource use and unit costs. Estimates of resource use were
based on treatment guidelines, the literature and interviews at
three major hospitals in Norway. Unit costs were based on tariffs,
price lists, hospital accounts and salary statistics. In the societal
perspective, costs were divided in three sections: Costs born by
patients (co-payments, transportation and value of time), costs
born by hospitals (personnel, medicines and supplies, laboratory
tests, capital and infrastructure) and other public costs (funding of
medicines). In the hospital perspective, net cost was calculated
(difference between expenses and income). RESULTS: From a
societal perspective the averagemonthly cost per patient is for PD:
30,700NOK (~3,800€) and for HD: 51,800NOK (~6,400€). The
main cost driver for PD is dialysis solutions: 23,800 NOK
(~2,900€). The cost components in HD are more homogeneous.
Hospitals go about break-even performing PDand have amonthly
net income of about 600 NOK (~75€) when performing HD.
CONCLUSION: For patients who can use either treatment
modality, PD is a cost saving alternative to HD from a societal
perspective. However, the ﬁnancing systems for dialysis in
Norway make hospitals relatively neutral from an economical
perspective in their choice of HD or PD for these patients.
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OBJECTIVES: Globally there is considerable variation in public
funding for IVF treatments. IVF is unique amongst health inter-
ventions because its success leads to human life. In light of this
uniqueness we apply a Generational Accounting approach, an
accepted method used by tax authorities, to assess whether pub-
licly funded IVF represents sound ﬁscal policy. Our assessment
considers future lifetime net tax contributions to the British
government (taxes paid minus transfer payments) attributed to a
successful IVF birth. METHODS: Net present value (NPV) cal-
culations were applied to the average cost per successful IVF
conceived live birth (£12,931 in 2005), lifetime direct cash trans-
fers and lifetime future tax contributions discounted using estab-
lished Treasury department rates. We assume the following:
full-time education aged 6–19; full-time employment aged 20–68
(Pension Commission, 2005); education costs, child-tax credits,
and pension contributions increase with inﬂation. Age-speciﬁc
income was adjusted for inﬂation over time, and we allowed
expected income to vary with age. Current government tax rev-
enues of 35.5% gross income were held constant. RESULTS:
Based on average life-expectancy the model indicates an
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individual born in 2005 returns a lifetime positive NPV to the
government of £160,069 with a break-even point (ie. where the
NPV becomes positive) at age 31. A child with similar charac-
teristics, but conceived using IVF, has a lifetime NPV of
£144,000 with a break-even point at age 33. Sensitivity analysis
indicated that these results are sensitive to assumptions about the
working age interval, inﬂation rate, discount rate, and increasing
age related health costs. CONCLUSION: Despite modelling limi-
tations, we conclude that under reasonable assumptions IVF
costs are relatively insigniﬁcant vis-à-vis other costs and beneﬁts
to government. While the model does not forecast the full eco-
nomic beneﬁts associated with investment in IVF, it does dem-
onstrate the potential long-term ﬁnancial returns of improved
access to IVF services.
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OBJECTIVES: To determine whether the protease inhibitor (PI)
darunavir boosted with low dose ritonavir (DRV/r) is cost-
effective, compared to currently available PIs, as part of highly
active anti-retroviral therapies (HAART), in highly pre-treated
HIV-1-infected adults who failed >1 PI-containing regimen in
European healthcare settings. This analysis included Belgium,
Italy and Sweden and focused on the payer perspective.
METHODS: A Markov model was adapted which contains 6
health states deﬁned by CD4+ T-cell-count range (<50, 51–100,
101–200, 201–350, 351–500 and >500 cells/mm3) and a state
“death” (Mauskopf et al, 2006). Clinical trial (POWER1&2)
data were used to model the composition of HAART regimens,
patient characteristics and transition probabilities during DRV/r
or comparator PI(/r) treatment, both combined with optimised
background regimen (OBR). After treatment failure, patients
were assumed to switch to tipranavir/r-containing regimens
((TPV/r)+OBR). Transition probabilities during TPV/r treatment
were obtained from published clinical trials. Utility values and
HIV-related mortality were obtained from published literature.
Published relative risks of non-HIV mortality in HIV patients
were applied to country-speciﬁc all-cause mortality statistics.
Non-HAART-related costs in each model state were derived from
observational studies in each country. Costs and effects were
discounted according to local guidelines. The quality-adjusted
lifetime incremental cost-effectiveness ratio (ICER) was calcu-
lated for the base-case. Univariate and probabilistic sensitivity
analyses were applied. RESULTS: For Sweden, Italy and Belgium
respectively, quality-adjusted life year (QALY) gains of 1.142,
1.171 and 1.397 were predicted for patients treated with DRV/r
in the base-case analysis. The base-case ICER for DRV/r was
12,211€/QALY, 16,668€/QALY and 12,584€/QALY respectively.
The DRV/r ICER remained consistently below the often quoted
threshold of 30,000€/QALY throughout extensive sensitivity
analyses. The probability of an ICER below 30,000€/QALY was
above 92% in all countries. CONCLUSION: DRV/r is predicted
to be cost-effective versus currently available PIs in highly pre-
treated HIV-1-infected adults in different European health care
settings.
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OBJECTIVES: To assess the cost-effectiveness of Intrathecal
Baclofen Therapy (ITB) versus current therapies in low level
disabled spasticity. METHODS: Two simulation models have
been constructed to assess the effectiveness, cost and cost-
effectiveness of various treatment sequences based on current
medical practices established by an international expert panel.
The ﬁrst model simulates current therapies using various
sequences of physical treatment only, oral treatments, focal spas-
ticity treatments, neuro-surgery and nursing. The second model
simulates strategies starting with ITB as the ﬁrst line treatment,
then various sequences of 2d, 3rd or 4th lines treatments includ-
ing ITB dose adjustment, explantation, oral treatments, focal
spasticity treatments, neurosurgery or nursing. The model used a
simulation decision framework and a 2-year time horizon over
four 6 months intervals. A successful treatment has been deﬁned
as a patient or caregiver satisfaction + change of 1 point in the
Ashworth score. Direct medical costs have been collected in the
frame of the French health care system. Effectiveness and cost
parameters have been included in the model according to speciﬁc
distribution shapes in order to take into account medical prac-
tices variability. Probabilistic sensitivity analyses were conducted
using 5000 Monte-Carlo simulations taking into account speciﬁc
distribution shapes for each cost and effectiveness parameters.
RESULTS: ITB as ﬁrst line strategy is the dominant strategy over
2 years, providing greater treatment success rate (78.7% versus
59.3%, p < 0.001), lower costs (59,391 Euros versus 88,272
Euros, p < 0.001) and lower cost-effectiveness (75,204 Euros/
success versus 148,822 Euros/success, p < 0.001) than current
strategies. CONCLUSION: This robust cost-effectiveness mod-
eling is the ﬁrst study assessing the cost-effectiveness of various
treatment sequences in disabled spasticity according to current
medical practices. This study establishes that introducing ITB as
the ﬁrst line therapy is a dominant strategy (more effective and
less costly) over a time period of 2 years.
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OBJECTIVES: To estimate the cost-effectiveness of a new treat-
ment (natalizumab) for multiple sclerosis (MS) compared to
current standard therapy with disease-modifying drugs (DMDs)
in Sweden. METHODS: A Markov model was constructed to
illustrate disease progression based on functional disability
(EDSS). Disease progression while on treatment with natali-
zumab was based on a two-year placebo-controlled clinical trial
in 942 patients (AFFIRM). Progression while on treatment with
current DMDs was estimated from a matched sample of 512
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